Search Result

Results for "

radionuclide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Radionuclide-Drug Conjugates (RDCs) (91) ADC Linker (1) Akt (1) Apoptosis (1) Autophagy (1) Bacterial (2) Biochemical Assay Reagents (50) Bombesin Receptor (1) Carbonic Anhydrase (1) CXCR (4) DNA-PK (1) Drug Derivative (1) Drug-Linker Conjugates for ADC (1) EGFR (1) Endogenous Metabolite (2) FAP (11) Fluorescent Dye (1) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Melanocortin Receptor (1) NF-κB (2) PARP (1) PD-1/PD-L1 (1) Peptide-Drug Conjugates (PDCs) (1) Prolyl Endopeptidase (PREP) (1) PSMA (11) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Ser/Thr Protease (1) Somatostatin Receptor (10) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (94) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	Azide (2) Alkynes (5)
Oligonucleotides:	Aptamers (1)

149

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Radionuclide-Drug Conjugates (RDCs)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106033

Edotreotide 1 Publications Verification DOTATOC; SDZ-SMT 487; SMT 487	Radionuclide-Drug Conjugates (RDCs)	Cancer
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as ⁹⁰Y, ¹⁷⁷Lu, and ⁶⁸Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .

HY-W283556

DO2A-tert-butyl ester	Biochemical Assay Reagents	Cancer
DO2A-tert-butyl ester is a bifunctional chelator (BFC) that can be used for the coupling of peptides and radionuclides. DO2A-tert-butyl ester can be used in the development of radionuclide imaging tracers .

HY-114377

p-SCN-Bn-DOTA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .

HY-147057

Rofapitide tetraxetan 2 Publications Verification FAP-2286	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .

HY-139564

DOTA Zoledronate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAP18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .

HY-114377R

p-SCN-Bn-DOTA (Standard)	Others	Cancer
p-SCN-Bn-DOTA (Standard) is the analytical standard of p-SCN-Bn-DOTA. This product is intended for research and analytical applications. p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .

HY-148761

Zadavotide guraxetan 2 Publications Verification PSMA I&T; PNT-2002	PSMA	Cancer
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as ⁶⁸Ga and ¹⁷⁷Lu) through DOTA to produce radioactive probes ([ ⁶⁸Ga]Ga/DOTA-NI-FAPI-04 and [ ¹⁷⁷Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-164589

NOPO	Radionuclide-Drug Conjugates (RDCs)	Cancer
NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164653

DOTAEt	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164590

BCN-NODAGA	Radionuclide-Drug Conjugates (RDCs)	Cancer
BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164599

TA-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-P10730

DOTA-Lanreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-P10731

DOTA-NAPamide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-P10732

DOTA-cyclo(RGDfK)	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164594

TA-DOTA-GA	Radionuclide-Drug Conjugates (RDCs)	Cancer
TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164592

DTPA-tetra(tBu)ester	Radionuclide-Drug Conjugates (RDCs)	Cancer
DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-W999782

Propargyl-DOTA-tris(tBu)ester	Radionuclide-Drug Conjugates (RDCs)	Cancer
Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164603

3p-C-NOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164596

THP(Bz3)-Glu	Radionuclide-Drug Conjugates (RDCs)	Cancer
THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164654

DOTA-PEG10-azide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-W999766

Propargyl-NOTA(tBu)2	Radionuclide-Drug Conjugates (RDCs)	Cancer
Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.

HY-W586475

Fluorescein-triazole-PEG5-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164591

THP(Bz)3-NH2	Radionuclide-Drug Conjugates (RDCs)	Cancer
THP(Bz)3-NH2 is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-159768A

DOTAGA.Glu.(FAPi)2	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41. HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-164593

NH-CH2-CH2-DOTAM	Radionuclide-Drug Conjugates (RDCs)	Cancer
NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-159767A

(S)-DOTAGA.(SA.FAPi)2	Radionuclide-Drug Conjugates (RDCs)	Cancer
(S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-164656

DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE	Drug-Linker Conjugates for ADC	Cancer
DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-164588

NH2-PEG4-NODA-GA	Radionuclide-Drug Conjugates (RDCs)	Cancer
NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.

HY-159770A

(S)-EB-FAPI-B2	Radionuclide-Drug Conjugates (RDCs)	Cancer
(S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-W873634

TRAP TRAP-Pr	Radionuclide-Drug Conjugates (RDCs)	Cancer
TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.

HY-164379

DOTA-PEG4-alkyne	Others	Cancer
DOTA-PEG4-alkyne is a linker, and can be used for the labeling of radionuclide .

HY-132989

Mal-Deferoxamine	Reactive Oxygen Species (ROS) Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs)	Cancer
Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .

HY-W011118

DTPA anhydride	Radionuclide-Drug Conjugates (RDCs)	Cancer
DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.

HY-W087187

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-160092

Martinostat	HDAC	Neurological Disease
Martinostat is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-160092A

Martinostat hydrochloride	HDAC	Neurological Disease
Martinostat hydrochloride is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-138134

NOTP	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-138269A

Barzuxetan hydrochloride CHX-A''-DTPA-NCS hydrochloride	Biochemical Assay Reagents	Others
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-134418A

NOTA trihydrochloride	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W088413

DOTA-amide	Biochemical Assay Reagents	Others
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Biochemical Assay Reagents	Others
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Type

HY-W283556

DO2A-tert-butyl ester	Chelators
DO2A-tert-butyl ester is a bifunctional chelator (BFC) that can be used for the coupling of peptides and radionuclides. DO2A-tert-butyl ester can be used in the development of radionuclide imaging tracers .

HY-W088413

DOTA-amide	Chelators
DOTA-amideis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-amide can be used for conjugation of peptides and radionuclides.

HY-W678394

DOTA-Thiol	Chelators
DOTA-Thiolis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-Thiol can be used for conjugation of peptides and radionuclides.

HY-W782078

Butyne-DOTA	Chelators
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717743

DOTAM-mono-acid	Chelators
DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.

HY-138134

NOTP	Chelators
NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.

HY-138269A

Barzuxetan hydrochloride CHX-A''-DTPA-NCS hydrochloride	Chelators
Barzuxetan (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Barzuxetan (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-134418A

NOTA trihydrochloride	Chelators
NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W726767

DO2A	Chelators
DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

HY-158072

DOTAM-NHS-ester	Chelators
DOTAM-NHS-esteris a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester can be used for conjugation of peptides and radionuclides.

HY-W717830

CB-Cyclam	Chelators
CB-Cyclamis a bifunctional chelator (Bifunctional Chelator; BFC), which is a main chain Cyclen derivative of the macrocyclic ligand tetradecane. CB-Cyclam can be used for conjugation of peptides and radionuclides.

HY-W717782

Bz-DTPA hydrochloride	Chelators
Bz-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Bz-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W250844A

DO3A trisodium	Chelators
DO3A (trisodium)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO3A (trisodium) can be used for conjugation of peptides and radionuclides.

HY-W087027A

Maleimide-NOTA TFA	Chelators
Maleimide-NOTA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. Maleimide-NOTA (TFA) can be used for conjugation of peptides and radionuclides.

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Chelators
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-W539916

Azido-mono-amide-DOTA	Chelators
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717779

4-Aminobutyl-DOTA	Chelators
4-Aminobutyl-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA can be used for conjugation of peptides and radionuclides.

HY-128890A

DOTA-NHS-ester hexafluorophosphate TFA	Chelators
DOTA-NHS-ester (hexafluorophosphate TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-NHS-ester (hexafluorophosphate TFA) can be used for conjugation of peptides and radionuclides.

HY-A0074

DTPA-tetra (t-Bu ester) tetra-tBu-DTPA	Chelators
DTPA-tetra (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. DTPA-tetra (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782087A

p-SCN-Bn-PCTA hydrochloride	Chelators
p-SCN-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-SCN-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717781A

p-NH₂-Bn-DTPA hydrochloride	Chelators
p-NH?-Bn-DTPA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W782088A

p-NH₂-Bn-PCTA hydrochloride	Chelators
p-NH?-Bn-PCTA (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-PCTA (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W802013

DOTA-4AMP	Chelators
DOTA-4AMPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTA-4AMP can be used for conjugation of peptides and radionuclides.

HY-158068

Maleimido-mono-amide-DTPA TFA	Chelators
Maleimido-mono-amide-DTPA (TFA)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DTPA (TFA) can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne	Chelators
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W451440

Butyne-DOTA-tris(t-butyl ester)	Chelators
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-131673A

(S)-p-SCN-Bn-TCMC hydrochloride	Chelators
(S)-p-SCN-Bn-TCMC (hydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (S)-p-SCN-Bn-TCMC (hydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride	Chelators
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-156138A

CB-TE2A tetrahydrochloride	Chelators
CB-TE2A (tetrahydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC), which is a TETA derivative of the macrocyclic ligand tetradecane backbone. CB-TE2A (tetrahydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W717833

NO2A-(t-Bu ester)	Chelators
NO2A-(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W782075

p-NO2-Bn-DOTA	Chelators
p-NO2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NO2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-48876

p-NH2-Bn-DOTA	Chelators
p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.

HY-W717742

p-NO2-Bn-Cyclen	Chelators
p-NO2-Bn-Cyclenis a bifunctional chelator (Bifunctional Chelator; BFC), which is a derivative of the macrocyclic ligand dodecane backbone Cyclen. p-NO2-Bn-Cyclen can be used for conjugation of peptides and radionuclides.

HY-158066

p-NH2-Bn-NOTA hydrochloride hydrate	Chelators
p-NH2-Bn-NOTA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-NH2-Bn-NOTA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-158069

p-NH₂-Bn-DTPA-penta (t-Bu ester)	Chelators
p-NH?-Bn-DTPA-penta (t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH?-Bn-DTPA-penta (t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W460274

4-Aminobutyl-DOTA-tris(t-butyl ester)	Chelators
4-Aminobutyl-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. 4-Aminobutyl-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W250929

Maleimido-mono-amide-DOTA-tris(t-Bu ester)	Chelators
Maleimido-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Maleimido-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-148646A

p-NH2-CHX-A"-DTPA hydrochloride hydrate	Chelators
p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.

HY-W749603

Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)	Chelators
Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-W749614

NO2A-Butyne-bis(t-Butyl ester)	Chelators
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W782081

p-SCN-Bn-oxo-DO3A	Chelators
p-SCN-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-SCN-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

HY-W717760

p-NH2-Bn-DOTA-tetra(t-Bu ester)	Chelators
p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.

HY-156038

(S)-p-SCN-Bn-DOTA	Chelators
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .

HY-W782080

p-NH2-Bn-oxo-DO3A	Chelators
p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name	Target	Research Area

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106033

Edotreotide 1 Publications Verification DOTATOC; SDZ-SMT 487; SMT 487	Radionuclide-Drug Conjugates (RDCs)	Cancer
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as ⁹⁰Y, ¹⁷⁷Lu, and ⁶⁸Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41. HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10758

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P10232

Hynic-toc HYNIC-Tyr3-octreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5053

Galacto-RGD	Radionuclide-Drug Conjugates (RDCs) Integrin	Cancer
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ ⁶⁸Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as ¹⁷⁷Lu and ²²⁵Ac. PSMA-D5 ([ ⁶⁸Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-153549

Pentixafor	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10012

Pendetide GYK-DTPA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-153550

PSMA-1007	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. ¹⁸F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Others
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10729A

DOTA-Bombesin (1-14) TFA	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-114133

Depreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10369

Betiatide	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Inflammation/Immunology
Betiatide, as a chelating agent for Technetium-99m ( ^99mTc), is used to prepare ^99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10846

HYNIC-CTP	Isotope-Labeled Compounds	Cardiovascular Disease
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide ^99mTc through HYNIC acting as a chelator, forming ^99mTc-HYNIC-CTP. ^99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-D2363

DOTA.SA.FAPi TFA	FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P5290

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P5126

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Cat. No.	Product Name	Target	Research Area

HY-P99566

Tenatumomab ST2146	Transmembrane Glycoprotein	Cancer
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .

Cat. No.	Product Name		Classification

HY-W782078

Butyne-DOTA		Alkynes
Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.

HY-P10758

Alkyne-βAG-TOCA		Alkynes
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W539916

Azido-mono-amide-DOTA		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-W749627

NO2A-Butyne		Alkynes
NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.

HY-W451440

Butyne-DOTA-tris(t-butyl ester)		Alkynes
Butyne-DOTA-tris(t-butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA-tris(t-butyl ester) can be used for conjugation of peptides and radionuclides.

HY-W717800A

NO2A-Azide trihydrochloride		Azide
NO2A-Azide (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Azide (trihydrochloride) can be used for conjugation of peptides and radionuclides.

HY-W749614

NO2A-Butyne-bis(t-Butyl ester)		Alkynes
NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.

Cat. No.	Product Name		Classification

HY-160059

JHIT2e aptamer sodium		Aptamers
JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

radionuclide

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products